---
figid: PMC4716672__nihms-705092-f0003
figlink: /pmc/articles/PMC4716672/figure/F3/
number: F3
caption: (A) Diagram of how the MAPK pathway, PI3K pathway, and p53 modulate protein
  synthetic machinery. (B) Pol I transcription can be regulated by many different
  mechanisms. This figure depicts the regulatory methods most relevant to melanoma.
  UBF, TBP, and TIF-IA can all be regulated by the MAPK pathway via ERK1/2. The PI3K/AKT/mTOR
  pathway regulates transcription through the phosphorylation of UBF and TIF-IA. AKT
  also regulates Pol I transcription through mTORC1-independent mechanisms. p53 is
  able to impair Pol I transcription by inhibiting SL1 binding to UBF. Nonspecific
  inhibitors of Pol I transcription include cisplatin, BMH-21, and CX-3543 which disrupt
  transcription through activity on genomic DNA. Drugs targeting signaling pathways
  can also exert effect through disruption of Pol I transcription. BRAF and MEK inhibitors
  impair ERK1/2 ability to activate UBF, TBP, and TIF-IA. TOR kinase inhibitors (TOR-KIs)
  and rapalogs impair the ability of mTOR to activate UBF and TIF-IA. PI3K/TOR-KIs
  also prevent feedback activation of PI3K by mTOR inhibition and prevent mTORC1-independent
  Pol I activation by AKT. CX-5461 acts independently of mTOR and MAPK pathways by
  preventing SL1 complex association. (C) eIF4F complex inhibition. mTOR regulates
  eIF4F activity through 4EBP1 and p70S6K. Rapalogs, TOR-KIs, PI3K/TOR-KIs, and amino
  acid starvation can all inhibit mTOR activity, thus reducing mRNA translation. Regulation
  of translation through the MAPK pathway can be inhibited at the point of MNK1/2
  by cercosporamide. Multiple drugs targeting the eIF4F complex are currently under
  investigation as potential cancer therapeutics. These include eIF4A inhibitors,
  inhibitors of eIF4E/eIF4G interaction, eIF4E cap-binding activity, and antisense
  oligonucleotide inhibitors of eIF4E. Furthermore, the biogenesis of 60S and 40S
  subunits necessary for mRNA translation can be impaired via ribosomal protein (RP)
  knockdown, or various Pol I disruptors. (D) Ternary complex inhibition. Activation
  of any of the eIF2α kinases causes phosphorylation of eIF2α, leading to sequestration
  of eIF2B, preventing GEF activity needed to continue translation. Many stresses
  can lead to kinase activation. Amino acid starvation or the mimicking of uncharged
  tRNA can activate GCN2. ER stress is a common activator of PERK. N,N’-diarylureas
  are activators of HRI, and PTEN activity independent of PI3K/AKT can lead to PKR
  activation. In addition, inhibitors of eIF2α phosphatase activity such as salubrinal
  can block eIF2B function.
pmcid: PMC4716672
papertitle: Therapeutic Interventions to Disrupt the Protein Synthetic Machinery in
  Melanoma.
reftext: Gregory R. Kardos, et al. Pigment Cell Melanoma Res. ;28(5):501-519.
pmc_ranked_result_index: '31325'
pathway_score: 0.9447859
filename: nihms-705092-f0003.jpg
figtitle: Therapeutic Interventions to Disrupt the Protein Synthetic Machinery in
  Melanoma
year: ''
organisms: Homo sapiens
ndex: a4814ae9-dea8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4716672__nihms-705092-f0003.html
  '@type': Dataset
  description: (A) Diagram of how the MAPK pathway, PI3K pathway, and p53 modulate
    protein synthetic machinery. (B) Pol I transcription can be regulated by many
    different mechanisms. This figure depicts the regulatory methods most relevant
    to melanoma. UBF, TBP, and TIF-IA can all be regulated by the MAPK pathway via
    ERK1/2. The PI3K/AKT/mTOR pathway regulates transcription through the phosphorylation
    of UBF and TIF-IA. AKT also regulates Pol I transcription through mTORC1-independent
    mechanisms. p53 is able to impair Pol I transcription by inhibiting SL1 binding
    to UBF. Nonspecific inhibitors of Pol I transcription include cisplatin, BMH-21,
    and CX-3543 which disrupt transcription through activity on genomic DNA. Drugs
    targeting signaling pathways can also exert effect through disruption of Pol I
    transcription. BRAF and MEK inhibitors impair ERK1/2 ability to activate UBF,
    TBP, and TIF-IA. TOR kinase inhibitors (TOR-KIs) and rapalogs impair the ability
    of mTOR to activate UBF and TIF-IA. PI3K/TOR-KIs also prevent feedback activation
    of PI3K by mTOR inhibition and prevent mTORC1-independent Pol I activation by
    AKT. CX-5461 acts independently of mTOR and MAPK pathways by preventing SL1 complex
    association. (C) eIF4F complex inhibition. mTOR regulates eIF4F activity through
    4EBP1 and p70S6K. Rapalogs, TOR-KIs, PI3K/TOR-KIs, and amino acid starvation can
    all inhibit mTOR activity, thus reducing mRNA translation. Regulation of translation
    through the MAPK pathway can be inhibited at the point of MNK1/2 by cercosporamide.
    Multiple drugs targeting the eIF4F complex are currently under investigation as
    potential cancer therapeutics. These include eIF4A inhibitors, inhibitors of eIF4E/eIF4G
    interaction, eIF4E cap-binding activity, and antisense oligonucleotide inhibitors
    of eIF4E. Furthermore, the biogenesis of 60S and 40S subunits necessary for mRNA
    translation can be impaired via ribosomal protein (RP) knockdown, or various Pol
    I disruptors. (D) Ternary complex inhibition. Activation of any of the eIF2α kinases
    causes phosphorylation of eIF2α, leading to sequestration of eIF2B, preventing
    GEF activity needed to continue translation. Many stresses can lead to kinase
    activation. Amino acid starvation or the mimicking of uncharged tRNA can activate
    GCN2. ER stress is a common activator of PERK. N,N’-diarylureas are activators
    of HRI, and PTEN activity independent of PI3K/AKT can lead to PKR activation.
    In addition, inhibitors of eIF2α phosphatase activity such as salubrinal can block
    eIF2B function.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - POLI
  - PRKAR2A
  - PRKAR2B
  - PIK3R4
  - TP53
  - PRKAR1B
  - EIF2AK1
  - MAP2K1
  - MAP2K2
  - PTEN
  - AKT3
  - MKNK2
  - MTOR
  - SLC1A5
  - MAPK1
  - MAPK3
  - EIF2AK4
  - PIK3R6
  - PIK3R5
  - RRN3
  - SLTM
  - ATP7A
  - AKT1
  - AKT2
  - PIK3CG
  - PIK3R3
  - PRKACA
  - PDCD4
  - EIF2AK3
  - PIK3CA
  - TBP
  - RAF1
  - BRAF
  - HRAS
  - MKNK1
  - PRKACB
  - PRKACG
  - PRKAR1A
  - KRAS
  - ARAF
  - PIK3CB
  - PIK3CD
  - NRAS
  - Halofuginone
  - Sinulariolide
  - Cercosporamide
  - Temsirolimus
  - Pateamine A
  - CGP 57380
  - Silvestrol
  - Hippuristanol
  - NVPBEZ235
  - AZD8055
  - GSK2126458
  - LY2275796
  - Met
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: Poli
  symbol: POLI
  source: hgnc_symbol
  hgnc_symbol: POLI
  entrez: '11201'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: HRI
  symbol: HRI
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK1
  entrez: '27102'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MNK1/2
  symbol: MNK2
  source: hgnc_alias_symbol
  hgnc_symbol: MKNK2
  entrez: '2872'
- word: mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ASCT2
  symbol: ASCT2
  source: hgnc_alias_symbol
  hgnc_symbol: SLC1A5
  entrez: '6510'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: GCN2
  symbol: GCN2
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK4
  entrez: '440275'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: TIF-IA
  symbol: TIF-IA
  source: hgnc_alias_symbol
  hgnc_symbol: RRN3
  entrez: '54700'
- word: Met
  symbol: Met
  source: hgnc_alias_symbol
  hgnc_symbol: SLTM
  entrez: '79811'
- word: MNK
  symbol: MNK
  source: hgnc_prev_symbol
  hgnc_symbol: ATP7A
  entrez: '538'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: P53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PDCD4
  symbol: PDCD4
  source: hgnc_symbol
  hgnc_symbol: PDCD4
  entrez: '27250'
- word: PERK
  symbol: PERK
  source: hgnc_alias_symbol
  hgnc_symbol: EIF2AK3
  entrez: '9451'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: TBP
  symbol: TBP
  source: hgnc_symbol
  hgnc_symbol: TBP
  entrez: '6908'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MNK1/2
  symbol: MNK1
  source: hgnc_alias_symbol
  hgnc_symbol: MKNK1
  entrez: '8569'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
chemicals:
- word: Halofuginone
  source: MESH
  identifier: C010176
- word: Sinulariolide
  source: MESH
  identifier: C050253
- word: Cercosporamide
  source: MESH
  identifier: C085452
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Pateamine A
  source: MESH
  identifier: C421324
- word: CGP 57380
  source: MESH
  identifier: C466997
- word: Silvestrol
  source: MESH
  identifier: C489897
- word: Hippuristanol
  source: MESH
  identifier: C510125
- word: NVPBEZ235
  source: MESH
  identifier: C531198
- word: AZD8055
  source: MESH
  identifier: C546624
- word: GSK2126458
  source: MESH
  identifier: C561454
- word: LY2275796
  source: MESH
  identifier: C569652
- word: Met
  source: MESH
  identifier: D008715
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4716672__F3
redirect_from: /figures/PMC4716672__F3
figtype: Figure
---
